Investigation of 2-phenylimidazo[1,2-]quinolines as potential antiproliferative agents.

It has been demonstrated that the lead compound 2-phenylimidazo[1,2-]quinoline selectively inhibits CYP1 enzymes. Additionally, CYP1 inhibition has been linked to inducing antiproliferative effects in various breast cancer cell lines as well as relieving drug resistance caused by CYP1 upregulation. Herein, 54 novel analogs of 2-phenylimidazo[1,2-]quinoline have been synthesized with varied substitution on the phenyl and imidazole rings.